CREATIVE MEDICAL
TECHNOLOGY HOLDINGS, INC.

A REGENERATIVE MEDICINE COMPANY ADVANCING DISRUPTIVE STEM CELL TECHNOLOGY PLATFORMS

CONFIDENTIAL CLINICAL PIPELINE PRESENTATION

August 2024

NASDAQ: CELZ

FORWARD-LOOKING STATEMENTS

The information contained in this presentation contains certain forward-looking statements. All statements other than statements of historical facts contained or incorporated by reference in this presentation, including statements regarding our future financial position, business strategy and plans and objectives of management for future operations, are forward-looking statements. The words “anticipate,” “believe,” “estimate,” “will,” “may,” “future,” “plan,” “intend” and “expect” and similar expressions generally identify forward-looking statements. These forward-looking statements are not guarantees and are subject to known and unknown risks, uncertainties and assumptions that may cause our actual results, levels of activity, performance or achievements to be materially different from any future results, levels of activity, performance or achievements expressed or implied by such forward-looking statements. Although we believe that our plans, intentions and expectations reflected in the forward-looking statements are reasonable, we cannot be sure that they will be achieved. Particular uncertainties that could cause our actual results to be materially different than those expressed in our forward-looking statements include: our history of losses; our inability to receive regulatory approval for our products; later discovery of previously unknown problems; reliance on third parties; competition between us and other companies in the industry; delays in the development of products; our ability to raise additional capital; continued services of our executive management team; and statements of assumption underlying any of the foregoing, as well as other factors set forth under the caption “Risk Factors” in our annual report on Form 10-K, and other subsequent filings, with the U.S. Securities and Exchange Commission. All subsequent written and oral forward-looking statements attributable to us, or persons acting on our behalf, are expressly qualified in their entirety by the foregoing. Except as required by law, we undertake no obligation to update any forward-looking statement, whether as a result of new information, future events or otherwise.

WHO IS CREATIVE MEDICAL TECHNOLOGY?

- We are focused on developing and marketing **breakthrough regenerative stem cell therapies**, including a potentially **revolutionary immunotherapy platform** for the treatment of multiple indications.
- We own an **extensive IP portfolio** grounded in regenerative medicine in the areas of immunology, endocrinology, urology, neurology, and orthopedics.
- We are **fully dedicated to supporting a growing network of physician partners** and developing additional therapeutic solutions that **improve patient quality of life** and **health outcomes**.

Headquarters	**Phoenix, AZ**
Year Formed / Reverse Merger	**2016**
Exchange / Ticker	**NASDAQ / CELZ**
NASDAQ Uplist Date	**December 2021**
Authorized Common Shares	**5 M**
Shares Outstanding	**1.4 M**
Warrants	**2.3 M**
Total Cash (06.30.24)	**$7.5 M**
Total Debt (06.30.24)	**$0.0 M**

SCALABLE TECHNOLOGIES



ROBUST DEVELOPMENT PIPELINE IN SUBSTANTIAL ADDRESSABLE MARKETS

Therapy / Indication	Patents Filed	Pre-Clinical	Clinical	Comments
AlloStem™ Platform				**Multiple Indications** Allogenic Perinatal Tissue Derived Cell Line
ImmCelz® Platform				**Multiple Indications** Ongoing Research University of Miami & Greenstone Bioscience
IPSCelz Platform				**Multiple Indications** Ongoing Research with Greenstone Bioscience
AlloStem™ Type 1 Diabetes				**Allogenic Cells** **IND cleared by FDA**
AlloStemSpine Chronic Lower Back Pain				**Allogenic (AlloStem™)** **IND cleared by FDA**
Type 1 Diabetes Brittle				**ImmCelz with Islet Transplant** ODD Approved
Alova™ Premature Ovarian Failure				**Allogenic OvaStem®**
OvaStem® Premature Ovarian Failure				**Autologous Cells**
StemSpine® Chronic Lower Back Pain				**Peer Reviewed Publication** Published in Journal of Translational Science

AlloStem™

Allogenic Human Tissue Derived Cell Program

- Immediately available, scalable “Universal” recipient product
- Immunomodulatory properties to help treat immune and endocrine based disorders
- Support ImmCelz®, OvaStem® and StemSpine® programs and others
- Support clinical trials for rapid translation
- Designated and proprietary Master Cell Bank and Drug Master File for US FDA

StemSpine

Journal of Translational Science

Research Article

StemSpine®: Autologous paraspinal administration of bone marrow aspirate for treatment of lower back pain caused by lumbar angina

Javier E Paino[1], Nicole Tuma[2], Thomas E Ichim[3], Courtney E Bartlett[4], and Jorge Tuma[5]

- 15 patients with over 24 months of data showing safety and efficacy
- Significant improvement in mobility and reduction in pain
- Pain changed from 8.9 at baseline to 4.3 at 30 days, sustained to 1.8 at 6 months and1.3 at 12 months

Next Generation StemSpine®
Is powered by AlloStem™
IND Cleared



Cells injected **around the disc**, not in the disc

Improve blood flow around the disc along with **repair and replace damaged tissue**

ADAPT Chronic Lower Back Pain

ClinicalTrials.gov

Go to the classic website

Record 2 of 2

The U.S. government does not review or approve the safety and science of all studies listed on this website.

Read our full disclaimer (https://clinicaltrials.gov/about-site/disclaimer) for details.

NOT YET RECRUITING

Safety, Tolerability, and Effectiveness of Intramuscular Injection of CELZ-201-DDT for the Treatment of Chronic Lower Back Pain (ADAPT)

ClinicalTrials.gov ID NCT06053242

Sponsor **Creative Medical** Technology Holdings Inc

Information provided by **Creative Medical** Technology Holdings Inc (Responsible Party)

Last Update Posted 2023-09-28

- Phase 1/2a
  - 24 Patients receive CELZ-201
    - 6 Million cells
    - 12 Million cells
    - 24 Million cells
  - 6 Patients receive placebo
- Ultrasound guided paraspinal Delivery
- Safety/Tolerability/Efficacy

CREATE-1 Type 1 Diabetes

ClinicalTrials.gov

Go to the classic website

Record 1 of 2

The U.S. government does not review or approve the safety and science of all studies listed on this website.

Read our full disclaimer (https://clinicaltrials.gov/about-site/disclaimer) for details.

RECRUITING

Safety and Efficacy of CELZ-201 in Patients With Recent Onset Type 1 Diabetes (CREATE-1)

ClinicalTrials.gov ID NCT05626712

Sponsor **Creative Medical** Technology Holdings Inc

Information provided by **Creative Medical** Technology Holdings Inc (Responsible Party)

Last Update Posted 2023-07-14

- Single site Phase 1/2a
  - 12 Patients receive CELZ-201
  - 6 Patients receive placebo
- Intraarterial Delivery
- Safety/Tolerability/Efficacy

SUPERCHARGED AUTOLOGOUS IMMUNOTHERAPY PLATFORM

The Process

1. Extract patient PBMC by (same as CAR-T)

2. Incubate PBMC with Secreted Factors from Stimulated AlloStem™ Cells

3. Culture under proprietary conditions to expand Supercharged Tregs and other immune cells from the patient

4. Inject back into patient



SUPERCHARGED AUTOLOGOUS IMMUNOTHERAPY PLATFORM POWERED BY ALLOSTEM™

ImmCelz® for Multiple Indications



The Concept

- Utilizes secreted factors from **AlloStem™** cells to **"reprogram"** the patient's own immune cells.
- Patient's cells are cultured and become **supercharged immune cells**. They are then harvested and injected back into the patient in less than 72 hours.
- Immune cells are significantly smaller in size than stem cells and **more effectively penetrate damaged areas** to induce repair and regeneration.

ImmCelz® optimizes a patient's own immune cells for treating multiple indications.

Tregs suppress T cell activation and proliferation. Hence, Tregs preserve a large population of undivided T cells under T cell activation

Allogeneic setting, Standard versus Rapamycin ImmCelz expansion method



T cells have proliferated extensively in the Activated T cells control

T cells were suppressed efficiently by ImmCelz generated via Rapamycin+Conditioned Media



iPSC – Allogenic Cell Program

- Induced pluripotent stem cell is the human adult version of the embryonic stem cell without ethical, legal or safety issues
- Collaboration with Greenstone Biosciences – Stanford spinout to create iPSCs
- Support ImmCelz® program

Differentiation of AlloStem derived iPSC – Islets

Day 0 & 1	Days 2 & 3	Days 4 & 5	Day 6
			
			
		Definitive Endoderm	Primitive Gut Tube

RAPID AUTOLOGOUS STEM CELL PLATFORM FOR PREMATURE OVARIAN FAILURE

OvaStem® Program

Issued patent covering use of “regenerative cells” for treatment of ovarian failure (age-associated female infertility). Studies show that stem cells can:

- Reduce ovarian fibrosis
- Accelerate maturation of immature oocytes
- Restore growth factor production damaged by aging

Milestones:

- Successful Pilot Study
- Orphan Drug Designation filed with FDA August 2022

Intellectual Property - 2024

Area	Application/Patent #	Description
Immunology	63395252	Prevention and Treatment of Reproductive Failure by Regenerative Cells and Adjuvants
Immunology	63351330	Generation of Conditioned Media from Inducible Pluripotent Stem Cell Derived Endothelial Progenitor Cells
Immunology	63389091	Overcoming TNF-alpha Blockade Resistance in Rheumatoid Arthritis by Regenerative T Regulatory Cell Therapy
Immunology	63248324	Suppression of Diabetes Using Exosomes from Stem Cell Programmed Myeloid Cells
Immunology	63270678	Regenerative T Regulatory Cells
Immunology	63351330	Generation of Conditioned Media from Inducible Pluripotent Stem Cell Derived Mesenchymal Stem Cells
Immunology	63297883	Regenerative CAR-T Cells
Immunology	63123380	Induction of Infectious Tolerance by Ex Vivo Reprogrammed Immune Cells
Immunology	63395836	Prevention and Treatment of Hair Loss
Endocrinology	63338417	Prevention of Menopause Associated Osteoporosis by Intra-ovarian Administration of Regenerative Cells
Endocrinology	63349976	Cellular Regenerative Therapeutics for Enhancement/Restoration of Endometrial Function
Immunology	10,792,310	Methods for Treatment of Premature Ovarian Failure and Ovarian Aging Using Regenerative Cells
Endocrinology	16759671	Augmentation of Fertility by Platelet Rich Plasma
Immunology	63343846	Repair of Ovarian Damage and Dampening of Inflammatory Microenvironment by Administration of Monocytic-Granulocytic Progenitors with Immune Modulatory Activities
Immunology	63340454	Immunological Enhancement of Stem Cell Activity in Treatment of Ovarian Failure
Immunology	63340450	Protection from Ovarian Failure by Low Dose Interleukin-2 Administration
Immunology	63340447	Stimulation of Ovarian Function Subsequent to Chemotherapy
Immunology	63343832	Cytokine Primed Regenerative Cells for Treatment of Ovarian Failure
Immunology	63343841	Degenerating Ovarian Microenvironment Resistant Mesenchymal Stem Cells
Immunology	15617813	Adipose Derived Immunotherapy of Recurrent Spontaneous Abortion
Immunology	63349297	Gene Therapeutics for Enhancement/Restoration of Endometrial Function
Immunology	15702735	Inducing and Accelerating Post-Stroke Recovery by Administration of Amniotic Fluid Derived Stem Cells
Immunology	15987739	Generation of Autologous Immune Modulatory Cells for Treatment of Neurological Conditions
Immunology	63313313	Methods for Quantifying Potency of Regenerative Immunotherapies

Intellectual Property - 2024

Area	Application/Patent #	Description
Urology	15590668	Methods of Treating Erectile Dysfunction
Immunology	8,372,797	Treatment of Erectile Dysfunction by Stem Cell Therapy
Urology	16799656	Extracorporeal Shock Wave Ultrasound for Enhancement of Regenerative Activities in Erectile Dysfunction
Immunology	63302228	Regenerative Cell Therapy for Viral Induced Sexual Dysfunction
Immunology	63331179	Enhancement of Cartilage Regenerative Activity of Stem Cell Populations Based on Reduction of Intra-Articular Cellular Material
Immunology	9,598,673	Treatment of Disc Degenerative Disease
Immunology	10,842,815	Perispinal Perfusion by Administration of T regulatory Cells Alone or in Combination with Angiogenic Cell Therapies
Immunology	63331183	Enhancement of Stem Cell Therapy for Cartilage Degeneration by Anti-Oxidant Pre-Conditioning
Immunology	63331186	Treatment of Cartilage Degeneration Using Myeloid Suppressor Cells and Exosomes Derived Thereof
Diagnostics	63340828	Exosome Based Assays for Determining Candidates for Osteoarthritis Stem Cell Therapy
Diagnostics	63338416	Cytokine Based Assessment of Recipient Ability to Respond to Stem Cell Therapy for Cartilage Regeneration
Immunology	63297876	Chimeric Antigen Receptor Regenerative Gamma Delta T Cells
Immunology	17585356	Treatment of Kidney Failure using Ex Vivo Reprogrammed Immune Cells
Immunology	17559985	Treatment of Liver Failure by Ex Vivo Reprogrammed Immune Cells
Immunology	17559970	Treatment of Heart Failure and/or Post Infarct Pathological Remodeling by Ex Vivo Reprogrammed Immune Cells
Immunology	63138776	Treatment of Diabetes Using Immune Cells Reprogrammed Ex Vivo by Regenerative Cells
Immunology	63208249	Prevention and/or Treatment of Type 1 Diabetes by Augmentation of Myeloid Suppressor Cell Activity
Immunology	63223245	Therapeutic Monocytic Lineage Cells
Immunology	63313313	Methods for Quantifying Potency of Regenerative Immunotherapies
Immunology	63414823	Treatment of Diabetes by Enhancement of Pancreatic Islet Engraftment Through Regenerative Immune Modulation
Immunology	63390759	Treatment of limb Ischemia by Bone Marrow Stem Cells And Modification of Diseased Microenvironment
Immunology	63391865	Potentiation of Bone Marrow Cell Activity by Co-administration with Oxytocin
Immunology	63395839	Prophylaxis and Treatment of Orthopox Viruses Using Regenerative cells and Products Thereof
Immunology	63395834	Prevention of Space Travel Associated Bone Density Loss by Regenerative Cell Populations

SUMMARY


Strong Management Team and Scientific Collaborators
Disruptive Technology in Regenerative Medicine
Robust Development Pipeline
Substantial Addressable Markets
High Potential Commercial Products
Development Catalysts on the Horizon

IR CONTACTS

Timothy Warbington, CEO
TimW@creativemedicaltechnology.com

Devin Sullivan
devin@equityny.com